---
title: Study of STIM1 Membrane Expression
nct_id: NCT04978948
overall_status: RECRUITING
sponsor: University Hospital, Brest
study_type: OBSERVATIONAL
primary_condition: Autoimmune Diseases
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04978948.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04978948"
ct_last_update_post_date: 2025-02-06
last_seen_at: "2026-05-12T06:44:22.413Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study of STIM1 Membrane Expression

**Official Title:** Study of STIM1 Membrane Expression During Autoimmune Diseases

**NCT ID:** [NCT04978948](https://clinicaltrials.gov/study/NCT04978948)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 670
- **Lead Sponsor:** University Hospital, Brest
- **Conditions:** Autoimmune Diseases
- **Start Date:** 2021-05-11
- **Completion Date:** 2027-05
- **CT.gov Last Update:** 2025-02-06

## Brief Summary

The aim of this study is to determine the expression of STIM1 in the plasma membrane of lymphocytes from patients suffering from different autoimmune diseases in order to identify new pathologies of interest presenting an over-expression of STIM1PM.

This would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 99 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Diagnosis of one of the autoimmune diseases

Exclusion Criteria:

* Treatment with rituximab in the previous 12 months
```

## Arms

- **Myasthénie** — Blood samples will be collected
- **Myopathie inflammatoire (Myosite)** — Blood samples will be collected
- **Neuropathie autoimmune** — Blood samples will be collected
- **Néphropathies autoimmunes** — Blood samples will be collected
- **Hépatite auto-immune** — Blood samples will be collected
- **Pancréatite auto-immune** — Blood samples will be collected
- **Purpura Thrombopénique Immunologique** — Blood samples will be collected
- **Dermatose bulleuse** — Blood samples will be collected
- **Thyroïdite autoimmune** — Blood samples will be collected
- **Sclérose en plaque** — Blood samples will be collected
- **Sclérose latérale amyotrophique** — Blood samples will be collected
- **Polyarthrite Rhumatoïde** — Blood samples will be collected
- **Spondylarthrite axiale** — Blood samples will be collected
- **controls** — Patients without autoimune desease\* Blood samples will be collected
- **Lichen plan buccal auto-immun (LPB)** — Blood samples will be collected
- **lichen plan buccal allo-immun liée à une GvHD (" Graft versus Host Disease ")** — Blood samples will be collected
- **Lupus érythémateux systémique** — Blood samples will be collected
- **Sclérodermie** — Blood samples will be collected

## Primary Outcomes

- **level of STIM1-PM** _(time frame: Day 0)_ — Membrane expression level of STIM1-PM on the surface of immune cells, measured by flow cytometry

## Secondary Outcomes

- **correlation between STIM1 expression and Clinical Score** _(time frame: Day 0)_

## Locations (4)

- CHRU de Brest - Service de rhumatologie, Brest, Brest, France — _RECRUITING_
- Centre Hospitalier des Pays de Morlaix, Morlaix, Brittany Region, France — _RECRUITING_
- Centre Hospitalier de Quimper, Quimper, Brittany Region, France — _RECRUITING_
- CHU de Martinique, Fort-de-France, Martinique, France — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chru de brest - service de rhumatologie|brest|brest|france` — added _(2026-05-12)_
- `locations.centre hospitalier des pays de morlaix|morlaix|brittany region|france` — added _(2026-05-12)_
- `locations.centre hospitalier de quimper|quimper|brittany region|france` — added _(2026-05-12)_
- `locations.chu de martinique|fort-de-france|martinique|france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04978948.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04978948*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*